Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
Abstract Background As one of the many breast cancer subtypes, human epidermal growth factor receptor 2 (Her2)-positive breast cancer has higher invasiveness and poor prognosis, although the advent of anti-Her2 drugs has brought good news to patients.However, the emergence of drug resistance still limits its clinical efficacy, so there is an urgent